Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| Phathom Pharmaceuticals, Inc. | 45,122 | reported | 19 May 2026 | tx 3+80,122 |
| Otonomy, Inc. | 27,500 | reported | 21 Jun 2022 | tx 8+152,500 |
| Nabriva Therapeutics AG | 11,989 | reported | 29 Jan 2023 | tx 79+3,667,998−408,738 |
| COLLEGIUM PHARMACEUTICAL, INC | 8,095 | reported | 20 May 2020 | tx 9+76,575 |
| Trius Therapeutics Inc | 0 | reported | 11 Sept 2013 | tx 9+51,000−66,116 |
| CADENCE PHARMACEUTICALS INC | 0 | reported | 19 Mar 2014 | tx 39+2,786,074−3,777,009 |
| HYPERION THERAPEUTICS INC | 0 | reported | 07 May 2015 | tx 5+10,500−10,500 |
| Cidara Therapeutics, Inc. | 0 | reported | 07 Jan 2026 | tx 23+190,225−41,100 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 19 May 2026 | GRANT_AWARD | Phathom Pharmaceuticals, Inc. | 24,122 | 0.00 USD | |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 1,400 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 875 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 875 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 450 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 550 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 2,125 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 550 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 11,100 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 20,500 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 2,125 | — | deriv |
| 07 Jan 2026 | OTHER | Cidara Therapeutics, Inc. | 550 | — | deriv |
| 18 Jun 2025 | GRANT_AWARD | Cidara Therapeutics, Inc. | 11,100 | 0.00 USD | deriv |
| 16 Apr 2025 | GRANT_AWARD | Phathom Pharmaceuticals, Inc. | 21,000 | 0.00 USD | |
| 16 Apr 2025 | GRANT_AWARD | Phathom Pharmaceuticals, Inc. | 35,000 | 0.00 USD | deriv |
| 17 Dec 2024 | GRANT_AWARD | Cidara Therapeutics, Inc. | 20,500 | 0.00 USD | deriv |
| 18 Jul 2024 | GRANT_AWARD | Cidara Therapeutics, Inc. | 2,125 | 0.00 USD | deriv |
| 22 Jun 2023 | GRANT_AWARD | Cidara Therapeutics, Inc. | 42,500 | 0.00 USD | deriv |
| 29 Jan 2023 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 431 | 1.50 USD | |
| 06 Jan 2023 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 11 | 1.30 USD | |
| 31 Dec 2022 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 5 | 1.89 USD | |
| 06 Dec 2022 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 9 | 2.02 USD | |
| 30 Nov 2022 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 5 | 2.25 USD | |
| 06 Nov 2022 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 10 | 2.24 USD | |
| 31 Oct 2022 | TAX_WITHHOLDING | Nabriva Therapeutics AG | 5 | 2.54 USD |
2 purchases reported after at least 12 months of silence — most recent on 14 Sept 2021.